Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
Amount Raised
$120 Million
Round Type
series b
Description
Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other new investors participating in the financing included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company, and an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX: 005250), also participated in the financing